Please login to the form below

Not currently logged in
Email:
Password:

fluticasone furoate

This page shows the latest fluticasone furoate news and features for those working in and with pharma, biotech and healthcare.

AZ’s COPD triple data sets up market clash with GSK

AZ’s COPD triple data sets up market clash with GSK

on LABA vilanterol, LAMA  umeclidinium and ICS fluticasone furoate - in the US and Europe last year. ... salmeterol and fluticasone propionate) that was a $7bn product at its peak but has seen sales slip of late, coming in at $3.3bn in the first nine

Latest news

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    The EU regulator cleared Trelegy (fluticasone furoate/umeclidinium/vilanterol) - considered to be the most important new product in the company’s ailing respiratory franchise - as a maintenance treatment in adults with ... GSK has been bringing other

  • CDC backs GSK’s Shingrix over Merck & Co’s Zostavax CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

    That helped offset continued declines for GSK’s past-its-prime asthma and chronic obstructive pulmonary disease (COPD) therapy Advair/Seretide (fluticasone propionate/salmeterol), which saw sales decline 7% to ... Nucala itself saw sales more than

  • With US approval, GSK now needs rapid uptake for COPD triple With US approval, GSK now needs rapid uptake for COPD triple

    The FDA approved Trelegy (fluticasone furoate/umeclidinium/vilanterol) for the long-term, once-daily maintenance treatment of COPD patients who suffer breakthrough exacerbations despite being treated with two-drug combinations. ... Specifically, Trelegy

  • GSK closes in on EU approval for triple COPD therapy GSK closes in on EU approval for triple COPD therapy

    The EMA's advisory committee gave its blessing for Trelegy/Elebrato (fluticasone furoate, umeclidinium and vilanterol) as a maintenance therapy for COPD patients who do not respond to two-drug therapy ... product, now facing sales declines because of

  • GSK preps COPD filing for asthma pioneer Nucala GSK preps COPD filing for asthma pioneer Nucala

    Aside from Nucala, GSK is pinning its near-term hopes on dolutegravir-based HIV therapies and its closed triple therapy for COPD – delivering inhaled corticosteroid (ICS) fluticasone furoate, long-acting beta

More from news
Approximately 5 fully matching, plus 33 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics